Shantou Institute of Ultrasonic Instrument
301602
Hubei Sinophorus Electronic Materials
688545
Pansoft
300996
4
Jiayu Holding
300117
5
Wuxi Taclink Optoelectronics Technology
688205
US Stock MarketDetailed Quotes
INCY Incyte
- 72.600
- -0.870-1.18%
Trading Jan 22 13:43 ET
13.99BMarket Cap806.67P/E (TTM)
73.515High71.975Low479.86KVolume73.470Open73.470Pre Close34.78MTurnover0.30%Turnover Ratio27.40P/E (Static)192.65MShares83.95052wk High4.41P/B11.65BFloat Cap50.35052wk Low--Dividend TTM160.46MShs Float153.150Historical High--Div YieldTTM2.10%Amplitude1.850Historical Low72.476Avg Price1Lot Size
About Incyte Company
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Company Profile
SymbolINCY
Company NameIncyte
Listing DateNov 4, 1993
Issue Price7.50
Founded1991
CEOMr. Herve Hoppenot
MarketNASDAQ
Employees2524
Fiscal Year Ends12-31
Address1801 Augustine Cut-Off
CityWilmington
ProvinceDelaware
CountryUnited States of America
Zip Code19803
Phone1-302-498-6700
Websitehttp://www.incyte.com
Company Executives
- Name
- Position
- Salary
- Herve Hoppenot
- Chairman of the Board, President and Chief Executive Officer
- 16.66M
- Christiana Stamoulis, M.B.A.
- Executive Vice President and Chief Financial Officer
- 5.08M
- Dr. Steven H. Stein, M.D.
- Executive Vice President and Chief Medical Officer
- 5.63M
- Thomas Tray
- Vice President and Chief Accounting Officer
- --
- Barry P. Flannelly, Pharm.D.
- Executive Vice President and General Manager, North America
- 4.09M
- Jonathan Elliott Dickinson
- Executive Vice President and General Manager, Europe
- --
- Paula J. Swain
- Executive Vice President, Human Resources
- --
- Michael James Morrissey
- Executive Vice President and Head of Global Technical Operations
- --
- Sheila A Denton
- Executive Vice President, General Counsel and Corporate Secretary
- --
- Vijay K. Iyengar
- Executive Vice President, Global Strategy and Corporate Development
- --
- Dr. Pablo J. Cagnoni, M.D.
- President and Head of Research and Development
- 15.83M
- Dr. Katherine A. High, M.D.
- Independent Director
- 454.76K
- Paul J. Clancy
- Independent Director
- 479.76K
- Jean-Jacques Bienaime
- Independent Director
- 478.76K
- Dr. Edmund P. Harrigan, M.D.
- Independent Director
- 482.26K
- Dr. Susanne Schaffert, PhD
- Independent Director
- 444.76K
- Julian C. Baker
- Lead Independent Director
- 512.76K
- Dr. Jacqualyn A. Fouse, PhD
- Independent Director
- 466.26K
- Dr. Otis W. Brawley,M.D.
- Independent Director
- 454.76K
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace